Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.

BACKGROUND: Observational studies from Asia suggest that maxingshigan-yinqiaosan may be effective in the treatment of acute H1N1 influenza. OBJECTIVE: To compare the efficacy and safety of oseltamivir and maxingshigan-yinqiaosan in treating uncomplicated H1N1 influenza. DESIGN: Prospective, nonblinded, randomized, controlled trial. (ClinicalTrials.gov registration number: NCT00935194) SETTING: Eleven hospitals from 4 provinces in China. PATIENTS: 410 persons [corrected] aged 15 to 69 [corrected] years with laboratory-confirmed H1N1 influenza. INTERVENTION: Oseltamivir, 75 mg twice daily; maxingshigan-yinqiaosan decoction (composed of 12 Chinese herbal medicines, including honey-fried Herba Ephedrae), 200 mL 4 times daily; oseltamivir plus maxingshigan-yinqiaosan; or no intervention (control). Interventions and control were given for 5 days. MEASUREMENTS: Primary outcome was time to fever resolution. Secondary outcomes included symptom scores and viral shedding determined by using real-time reverse transcriptase polymerase chain reaction. RESULTS: Significant reductions in the estimated median time to fever resolution compared with the control group (26.0 hours [95% CI, 24.0 to 33.0 hours]) were seen with oseltamivir (34% [95% CI, 20% to 46%]; P < 0.001), maxingshigan-yinqiaosan (37% [CI, 23% to 49%]; P < 0.001), and oseltamivir plus maxingshigan-yinqiaosan (47% [CI, 35% to 56%]; P < 0.001). Time to fever resolution was reduced by 19% (CI, 0.3% to 34%; P = 0.05) with oseltamivir plus maxingshigan-yinqiaosan compared with oseltamivir. The interventions and control did not differ in terms of decrease in symptom scores (P = 0.38). Two patients who received maxingshigan-yinqiaosan reported nausea and vomiting. LIMITATIONS: Participants were young and had mild H1N1 influenza virus infection. Missing viral data precluded definitive conclusions about viral shedding. CONCLUSION: Oseltamivir and maxingshigan-yinqiaosan, alone and in combination, reduced time to fever resolution in patients with H1N1 influenza virus infection. These data suggest that maxingshigan-yinqiaosan may be used as an alternative treatment of H1N1 influenza virus infection. PRIMARY FUNDING SOURCE: Beijing Science and Technology Project and Beijing Nova Program.

Risk factors for drug resistance in pulmonary tuberculosis inpatients.

OBJECTIVE: To analyze risk factors for drug resistance in pulmonary tuberculosis (PTB) inpatients. METHODS: Medical records of PTB inpatients in Chengdu Tuberculosis Hospital (CTH) from 2005 to 2007 were investigated retrospectively. A logistic regression model was used to analyze data. RESULTS: A total of 330 records were included in the analysis. A history of tuberculosis treatment was associated with drug resistance with odds ratio (OR) 16.79 and 95% confidence interval (95% CI) [10.14, 27.80] for all patients. Among new patients, the significant risk factor was duration of illness (OR 0.27, 95% CI [0.16, 0.46]), and for previously treated patients, risk factors included age (OR 0.96, 95% CI [0.93, 0.99]), improper initial chemotherapy (OR 3.85, 95% CI [1.59, 10.00]), and improper handling by medical staff (OR 3.44, 95% CI [1.32, 8.96]). CONCLUSIONS: A history of drug treatment is associated with drug resistance among PTB inpatients. Initial resistance becomes increasingly serious till 2007. To minimize the development of resistance, more personalized treatment and supervision should be used, and better training for medical staff is needed.